A r t i c l e s Biomarker discovery is motivated by the desire to identify reliable indicators of disease for risk assessment, early detection, predicting patient responses to therapies and surveillance of recurrent disease 1, 2 . So far, a broad range of distinct biological species such as metabolites 3 , peptides 4 , proteins 2,5 , cell-free nucleic acids 6 , exosomes 7 and circulating tumor cells 8 have been developed into biomarkers of varying performance. However, the use of naturally occurring biomarkers to indicate disease is limited by fundamental technical and biological challenges because biomarkers are frequently found in low concentrations in the circulation 8, 9 , are difficult to resolve in complex biological fluids 5 and can be degraded rapidly both in vivo and ex vivo 10 .
An alternative to endogenous biomarkers is the systemic administration of exogenous agents to interrogate biological states. These approaches offer the potential to tailor agents to exploit host physiology or interface with disease-specific molecular processes as alternative indicators of disease. Examples include polysaccharide inulin to assess glomerular filtration rates, fluorodeoxyglucose positron emission tomography (PET) to unveil regions of increased glucose metabolism and a suite of molecular and activity-based probes for imaging biological activities in vivo [11] [12] [13] . Because these agents can be designed and tested in vitro and in preclinical models, they can be iteratively optimized and administered at concentrations substantially above biological background. The limitations of these approaches include the inability to monitor a large family of probes simultaneously because of limited multiplexing capabilities and the substantial infrastructure of in vivo analyses, which require patients to be on site (e.g., PET and magnetic resonance imaging) and preclude remote data or sample collection.
Here we describe a class of engineered nanoscale agents that passively accumulate in diseased tissues from the host circulation through organ-or disease-specific vascular fenestrations (e.g., liver sinusoid endothelium or angiogenic tumor vessels, respectively) 14, 15 . After arrival in the diseased microenvironment, they are cleaved by aberrantly active proteases, releasing surface-conjugated, massencoded peptide substrates into the host urine for detection by mass spectrometry as synthetic biomarkers of disease ( Fig. 1) . Because dysregulated protease activities are implicated in a wide range of human diseases, including cancer, fibrosis, atherosclerosis, inflammation, Alzheimer's disease and many others 16 , highly multiplexed monitoring of aberrant protease activities has the potential to distinguish diverse disease states. Here we describe the application of this technology to noninvasively monitor liver fibrosis 17 and detect early stage cancers 18 .
RESULTS

Protease-sensitive nanoparticles for urinary monitoring
To develop a protease-sensing platform, we first identified peptide substrates of proteases implicated in liver fibrosis and cancer.
Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease Biomarkers are becoming increasingly important in the clinical management of complex diseases, yet our ability to discover new biomarkers remains limited by our dependence on endogenous molecules. Here we describe the development of exogenously administered 'synthetic biomarkers' composed of mass-encoded peptides conjugated to nanoparticles that leverage intrinsic features of human disease and physiology for noninvasive urinary monitoring. These protease-sensitive agents perform three functions in vivo: they target sites of disease, sample dysregulated protease activities and emit mass-encoded reporters into host urine for multiplexed detection by mass spectrometry. Using mouse models of liver fibrosis and cancer, we show that these agents can noninvasively monitor liver fibrosis and resolution without the need for invasive core biopsies and substantially improve early detection of cancer compared with current clinically used blood biomarkers. This approach of engineering synthetic biomarkers for multiplexed urinary monitoring should be broadly amenable to additional pathophysiological processes and point-of-care diagnostics.
A r t i c l e s
We conjugated fluorescein-labeled derivatives of ~50 candidate peptide substrates [19] [20] [21] [22] [23] to polyethylene glycol-coated, long-circulating iron oxide nanoworm nanoparticles 24 (Supplementary Fig. 1a -c) and incubated them with recombinant proteases commonly overexpressed in disease (e.g., matrixmetalloproteases (MMPs) and cathepsins) as well as blood-borne proteases to assess crossreactivity (e.g., FXa, tissue factor and thrombin). We determined the relative substrate activities for each protease-substrate combination by monitoring increases in sample fluorescence resulting from peptidolysis that allowed previously homoquenched fluorophores to emit freely in solution ( Fig. 2a) . We compiled the initial reaction velocities for comparative analysis in a heat map ( Fig. 2b) , from which we selected ten peptide substrates (S1-S10; Table 1 ) with broad protease susceptibility as our peptide-nanoworm library.
To establish the potential to probe disease microenvironments remotely from urine, we next investigated the in vivo behavior of each system component (i.e., peptide and nanoworm). We selected a xenobiotic mouse model of liver fibrosis in which FVB/NJ mice fed with 3,5diethoxycarbonyl-1,4-dihydrocollidine (DDC) develop progressive liver disease as a result of chronic bile duct injury 25 , leading to liver fibrosis and upregulation of local MMPs. First, to determine the efficiency of peptide clearance into urine, we selected the peptide glutamatefibrinopeptide B (Glu-fib, EGVNDNEEGFFSAR) as a prototypic urinary marker because its endogenous derivative (fibrinopeptide B) is biologically inert and filters freely into urine when released during coagulation 26 . Fluorophore-labeled Glu-fib administered intravenously (i.v.) cleared rapidly into urine in both fibrotic and healthy mice with no evidence of hepatic uptake at the site of disease ( Fig. 2c) . By contrast, peptide-free nanoworms localized predominantly to the liver ( Fig. 2d ) but were unable to filter into urine, consistent with the renal clearance threshold of ~5 nm for inorganic nanoparticles 27 (nanoworms are ~40 nm in diameter; Supplementary Fig. 1a ) as well as our previous pharmacokinetic studies with nanoworms 28 . Infusion of peptide-nanoworms conjugated with fluorescent derivatives of substrates S1-S10 ( Table 1) resulted in strong liver uptake and elicited a marked urinary response in fibrotic mice from renal filtration of cleaved peptide fragments ( Fig. 2e) . Collectively, these studies demonstrated the ability of nanoworms to redirect peptides to sites of disease to facilitate the production of urinary biomarkers.
Profiling protease activities by mass spectrometry
Despite the multiplexing advantages of mass encoding, one challenge of detecting protease activity by mass spectrometry is that peptide substrates in complex proteolytic environments can be cleaved at multiple sites by promiscuous proteases and truncated by exoproteases 29, 30 to produce diverse pools of poorly defined fragments that confound mass analysis. Here we created well-defined mass reporters to encode our substrate library. In light of the favorable renal clearance properties of Glu-fib, we appended d isomer-rich derivatives of Glu-fib to the N terminus of each protease substrate to serve as protease-resistant mass reporters and promote renal filtration after substrate cleavage and release from nanoworms. We further modified these tandem peptides with internal photolabile residues 31 to enable the recovery of Glu-fib peptides by photolysis from complex urinary cleavage fragments after in vivo proteolysis. To test this construct, we synthesized a model photocaged tandem peptide (compound I; Fig. 3a ). Consistent with previously published reports on nitrophenyl groups, exposure of compound I (triply charged, 881.7 massto-charge ratio (m/z); Fig. 3b ) to UV light triggered peptide cleavage, resulting in the appearance of doubly charged, acetamide-terminated Glu-fib (785.4 m/z; Fig. 3b ).
To design an extensible encoding strategy for our library of protease substrates, we adapted principles of isobaric mass encoding 32, 33 to produce a family of mass reporters from Glu-fib. The distinguishing feature of an isobaric encoding strategy is that individual members within a family of reporters share a parent mass to facilitate efficient peptide collection by mass spectrometry but can be subsequently identified by unique tandem mass spectrometry (MS/MS) ions after fragmentation. Because Glu-fib fragments into C-terminal y-type ions ( Supplementary Fig. 2a ), we constructed ten mass codes centered on the y 6 ion (GFFSAR) by enriching the hexamer with heavy amino acids to produce variants differentiated by 1 Da each ( Supplementary  Fig. 2b ). We then balanced this introduced mass shift by isotope enrichment within the remaining residues (EGVNDNEE) to produce peptides with identical parent masses but distinct y 6 fragment ions. We call this encoding method isobar coded reporters (iCORE). To validate this approach, we analyzed an equimolar 10-plex iCORE Table 1 ) by liquid chromatography MS/MS (LC-MS/MS) and found the entire peptide library to be present initially as a single, unresolved peak (extracted ion chromatogram (XIC), 789.85 m/z; Fig. 3c,d ) but then resolve after fragmentation as predicted into a ten-peak spectrum with no fragmentation bias (683.4-692.4 m/z; Fig. 3e and Supplementary Fig. 3 ). We removed confounding peak overlap from naturally occurring isotopes (e.g., 13C) by collecting iCORE peptides with a 1-m/z window centered on the precursor ion ( Supplementary Fig. 4a ), which minimized the signal from naturally occurring isotopes to ~5% of the parent peak ( Supplementary Fig. 4b ). Consequently, in samples spiked with reporters at defined ratios (1:2:3:5:10:10:5:3:2:1), we found a linear correlation between peak intensity and stoichiometry in both unmodified and peak-subtracted analyses (n = 3 spiked samples, R 2 = 0.99 and R 2 = 0.99, respectively; Supplementary Fig. 5a-c) . We peak adjusted all subsequent samples to reflect contributions from naturally occurring isotopes.
To test the ability of iCORE reporters for monitoring peptide cleavage, we extended protease substrates S1-S10 with iCORE mass tags R1-R10 using photosensitive amino acids and coupled them to nanoworms to produce synthetic biomarkers G1-G10 ( Table 1) . After treatment of an equimolar cocktail of G1-G10 with recombinant MMP9, we isolated cleavage products by size filtration and exposed them to UV light to release reporters R1-R10 for MS/MS quantification. Collective substrate activities had distinct iCORE landscapes with individual y 6 peak intensities corresponding to the substrate preference for MMP9 ( Fig. 3f) . We applied this library to several additional proteases (Supplementary Fig. 6a ) and found that their iCORE profiles were unique, as determined from Pearson's correlation analysis (i.e., MMP2, MMP9, MMP12 and thrombin; Supplementary Fig. 6b ), illustrating the ability of iCORE-encoded nanoworms to monitor many protease-substrate combinations simultaneously.
Monitoring hepatic fibrogenesis and resolution
Liver fibrosis is a wound-healing response to chronic liver injury and results in the deposition of scar tissue that can lead to cirrhosis, liver failure and cancer 17 . The dynamics of extracellular matrix (e.g., collagen) accumulation are driven largely by activated hepatic stellate cells and matrix remodeling proteases such as MMPs and their inhibitors. The current gold standard for monitoring this process is a needle biopsy followed by histological analysis; however, this technique is invasive, confounded by high sampling heterogeneity, carries a finite risk of complications and cannot be performed as frequently as needed (e.g., for assessing antifibrotic therapies) 34 . Noninvasive assays, including ultrasound imaging, elastography and Table 1 10-plex synthetic biomarker library Synthetic biomarker library a,b (G1-G10) Substrate (S1-S10) Isobaric mass code c,d (R1-R10) y 6 reporter [y 6 +H + ] e +3 G +6 VndneeGFfsAr-X-K(FAM)GGPQGIWGQC-NW PQGIWGQ e +3 G +6 VndneeGFfsAr GFfsAr 683.4 e +2 G +6 Vndnee +1 GFfsAr-X-K(FAM)GGLVPRGSGC-NW LVPRGSG e +2 G +6 Vndnee +1 GFfsAr +1 GFfsAr 684.4 e +1 G +6 Vndnee +2 GFfsAr-X-K(FAM)GGPVGLIGC-NW PVGLIG e +1 G +6 Vndnee +2 GFfsAr +2 GFfsAr 685.4 eG +6 Vndnee +2 GFfs +1 Ar-X-K(FAM)GGPWGIWGQGC-NW PWGIWGQG eG +6 Vndnee +2 GFfs +1 Ar +2 GFfs +1 Ar 686.4 eG +5 VndneeGFfs +4 Ar-X-K(FAM)GGPVPLSLVMC-NW PVPLSLVM eG +5 VndneeGFfs +4 Ar GFfs +4 Ar 687.4 e +3 G +1 Vndnee +1 GFfs +4 Ar-X-K(FAM)GGPLGLRSWC-NW PLGLRSW e +3 G +1 Vndnee +1 GFfs +4 Ar +1 GFfs +4 Ar 688.4 e +3 GVndneeG +6 FfsAr-X-K(FAM)GGPLGVRGKC-NW PLGVRGK e +3 GVndneeG +6 FfsAr G +6 FfsAr 689.4 e +2 GVndneeG +6 Ffs +1 Ar-X-K(FAM)GGf(Pip)RSGGGC-NW f(Pip)RSGGG e +2 GVndneeG +6 Ffs +1 Ar G +6 Ffs +1 Ar 690.4 e +1 GVndnee +2 G +6 FfsAr-X-K(FAM)GGfPRSGGGC-NW fPRSGGG e +1 GVndnee +2 G +6 FfsAr +2 G +6 FfsAr 691.4 eGVndnee +3 G +6 FfsAr-X-K(FAM)GGf(Pip)KSGGGC-NW f(Pip)KSGGG eGVndnee +3 G +6 FfsAr +3 G +6 FfsAr 692.4
List of synthetic biomarkers (G1-G10), protease substrates (S1-S10) and isobaric mass reporters (R1-R10) used in study. Thus, there remains an urgent need for noninvasive biomarkers to replace biopsy-based monitoring to facilitate the identification and validation of new antifibrotic agents and support clinical decision making 36 . We sought to identify synthetic biomarkers with the capacity to monitor liver fibrosis and resolution and extended our DDC model to include both aspects of the disease. We first evaluated the potential toxicity of nanoworms to determine whether serial monitoring could be performed safely. Nanoworms are composed of iron oxide cores that are approved by the US Food and Drug Administration for use in humans (e.g., Feridex); we further examined whether fibrotic livers could be sensitized to nanomaterial toxicity. To investigate nanomaterial safety, we administered peptidenanoworms (1 mg per kg body weight) or PBS weekly (day 0, 7 and 14) to mice fed DDC or control chow for 3 consecutive weeks (Supplementary Fig. 7a ) and found that nanoworms did not exacerbate fibrosis, decrease body weight or induce hepatotoxicity compared to PBS ( Supplementary Fig. 7b-e ). Serial nanoworm infusions could also introduce experimental artifacts if residual urinary reporters from prior administrations are insufficiently cleared. Analysis of urine samples after the last nanoworm injection (day 14) revealed that both residual fluorescent and mass reporters were cleared within 5 d (day 19) ( Supplementary Fig. 7f,g) . Collectively, these experiments showed that nanoworms are well tolerated at the dosage selected and require 5 d for full clearance.
We next investigated whether urinary responses are specifically produced by fibrosis-associated proteases such as MMPs by testing urinary sensitivity to pharmacological inhibition of MMPs (Fig. 4a) . Whereas infusion of our 10-plex iCORE-encoded nanoworm cocktail (G1-G10) in mice given DDC chow for 3 weeks resulted in a strong increase in ensemble urinary fluorescence over mice given control chow (P < 0.001 by analysis of variance (ANOVA); Fig. 4b) , urinary responses were significantly attenuated in mice additionally treated with the broad-spectrum MMP inhibitor Marimastat by oral gavage for 2 d before nanoworm administration, resulting in over 70% inhibition of urinary fluorescence (P < 0.01; Fig. 4b) .
To determine the accessibility of nanoworms to sites of fibrosis, we performed immunofluorescence analysis of liver sections, which revealed that most nanoworms infiltrated freely into the parenchyma and further penetrated periportal zones of active fibrosis, escaping sequestration by resident macrophages (Supplementary Fig. 8a) . Compared to control sections, these regions showed substantial upregulation of MMP9, a representative fibrosis-associated MMP (Supplementary Fig. 8b,c) . Fibrotic sections treated with DQ gelatin substrates had similar punctate patterns ( Supplementary Fig. 8d) , confirming the enzymatic activity of collagen-degrading proteases (e.g., MMP2 and MMP9). These results showed that MMPs upregulated during fibrosis are proteolytically active and largely responsible for urinary responses.
We next monitored the processes of fibrosis and resolution by iCORE mass analysis to determine the response of individual biomarkers apart from their collective fluorescence in urine. Mice treated transiently with DDC for 3 weeks and then given DDC-free chow developed distinct fibrosis and resolution windows (0-3 and 7-11 weeks, respectively; Fig. 4c ), as verified macroscopically by Sirius red collagen staining of liver sections and hydroxyproline quantification ( Fig. 4d,e ). With this treatment regime, the amount of liver collagen increased approximately threefold compared to pretreatment amounts after 3 weeks on DDC (P < 0.005), persisted from week 3-7 after initial removal of DDC and significantly decreased from week 7-11 (P < 0.05 by ANOVA) after sustained DDC withdrawal (n = 3). Thus, to monitor the transitions between fibrosing and resolving disease, we administered nanoworms at 0, 3, 7 and 11 weeks into DDC-treated and age-matched control mice and then performed iCORE MS/MS analysis.
The resulting activities of the ten synthetic biomarkers showed markedly divergent kinetics (Fig. 4f) . The activities of biomarkers G3 and G4 both strongly increased relative to pretreatment baselines, reaching a plateau by week 11 despite staggered onset at weeks 7 and 3, respectively (P < 0.01). G5 and G6 showed opposing kinetics, significantly decreasing (P < 0.01) at week 3 before either gradually returning to pretreatment intensities (G5) or persisting to week 11 (G6). G7 tracked with the kinetics of DDC treatment, elevating sharply at week 3 and then rapidly reversing at week 7 (P < 0.01 by repeated npg measures ANOVA and Tukey's post test). None of the remaining biomarkers (G1, G2, G8, G9 and G10) deviated from their initial pretreatment activities (n = 10 DDC-treated mice), which was also true for all biomarkers in control mice (Supplementary Fig. 9 ).
Having identified a set of putative biomarkers for liver fibrosis in the context of DDC, we next sought to crossvalidate promising biomarkers in mice with deletion of Mdr2 (also known as Abcb4), a mechanistically distinct model of liver fibrosis. Crossvalidating biomarker responses in an independent cohort not involved in hypothesis generation is crucial for eliminating potential model-specific artifacts from the use of inbred mice as well as from data overfitting 37 . Mdr2 −/− mice lack a crucial phospholipid transporter that is required for bile stabilization and develop chronic liver injury from birth as a result of bile leakage to the portal tract 38 .
At 8 weeks of age, Mdr2 −/− mice showed evidence of periportal fibrosis as well as significant upregulation of MMP9 compared to age-matched wild-type mice ( Fig. 4g and Supplementary Fig. 10a,b) . From our library of ten probes, we selected G7 for crossvalidation because it was highly specific for liver fibrosis in our DDC study, tracking with fibrogenesis and declining after fibrotic resolution (Fig. 4f) . Similar to our initial observations, we detected significant elevations in urinary fluorescence in 8-week-old Mdr2 −/− mice over wild-type mice (Fig. 4h,i) . By contrast, G8, a biomarker revealed to be unresponsive in our DDC studies, did not show potential for monitoring fibrosis in Mdr2 −/− mice (Fig. 4i) . Collectively, these results further corroborated the ability of G7 to track liver fibrosis and underscored the potential for monitoring fibrogenesis with distinct molecular etiologies.
To explore potential improvements in disease classification that could be gained by using more than one biomarker, we further analyzed biomarker responses in our DDC study using receiver operating characteristic (ROC) curves. ROC curves characterize the predictive power of a biomarker by returning the area under the curve (AUC) as a metric, with a baseline AUC of 0.5 representing a random biomarker classifier (Supplementary Figs. 11-13 ). Within the 0-3 week fibrogenesis window, biomarkers G4, G5, G6 and G7 each discriminated disease with high sensitivity and specificity with associated AUCs ranging from 0.83 to 0.96 ( Supplementary Fig. 11) , and combinatorial panels, such as the best dual (G5 and G7) and triple (G5, G6 and G7) biomarker combinations, led to improvements in predictivity (0.98 and 1.0, respectively; Supplementary Fig. 13) . Conversely, during fibrotic resolution, the ability of candidate biomarkers, such as G1 (AUC = 0.73), to track disease was improved in the dual (G1 and G9, AUC = 0.9) and triple (G1, G7 and G9, AUC = 0.91) biomarker combinations (Supplementary Fig. 13) .
Collectively, these experiments demonstrated that liver fibrosis and resolution are revealed by distinct collections of synthetic biomarkers and multiplexed combinations allowed the highest diagnostic performance, illustrating the ability of this platform to noninvasively illuminate otherwise inaccessible aspects of liver disease evolution.
Early detection of colorectal cancer
When diagnosed before systemic dissemination, many primary tumors can be treated effectively with conventional clinical interventions 39 . However, the rates at which most biomarkers are shed from tumors are prohibitively low and cannot be readily augmented 40 , precluding 
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A r t i c l e s early detection 9, 18 . Thus there remains a stark mismatch between the smallest tumors detectable by blood biomarkers (>2-5 cm) and the size of tumors that would best respond to treatment (<1-5 mm), resulting in delayed detection, low drug-response rates and reduced overall patient survival. Here we hypothesized that because nanoparticles can passively target tumors to sample proteases through fenestrated angiogenic tumor vessels 15 , cancer-specific proteases could be co-opted to amplify tumor detection through sustained enzymatic release of synthetic urinary biomarkers.
To explore this hypothesis, we compared carcinoembryonic antigen (CEA), a clinically used blood biomarker for colorectal cancer (CRC), with our nanoworms. Because plasma CEA concentrations in patients with CRC are highly variable, we first compiled CEA production rates documented by the American Type Culture Collection from 24 established human CRC lines (14 additional lines were uncharacterized) and found the rates to have a range of well over 4 log units and a median value of 1.65 ng per 10 6 cells per 10 d ( Supplementary  Fig. 14) . We selected the cell line LS174T to represent colorectal tumors capable of producing CEA near the maximum observed rates (~100× above the median) and validated its ability to secrete CEA in vitro by enzyme-linked immunosorbent assay (ELISA) that had a detection limit of ~0.1 ng ml −1 (Supplementary Fig. 15a,b) . To fully capture the broad spectrum of activities from matrix remodeling proteases shared by most invasive tumors, we infused our biomarker ensemble (G1-G10) into mice bearing LS174T flank tumors (Fig. 5a,b) and detected a significant rise in urinary fluorescence. We verified nanoworm extravasation into the tumor parenchyma by fluorescence imaging of excised tumors and analysis of tissue sections ( Supplementary Fig. 16a,b) . To test whether urinary responses were specifically produced by proteolysis from MMPs, we treated a separate cohort of tumor-bearing mice with Marimastat for 2 d before G1-G10 administration. Pharmacological inhibition of MMPs resulted in near abrogation of urinary signals, reducing the signal intensities by ~73% (Fig. 5b) .
We next directly compared synthetic urinary biomarkers to CEA for early cancer detection. After implantation of LS174T cells, we monitored tumor growth noninvasively by quantifying serum CEA concentrations every 3 d by ELISA, which revealed disease by day 13 when the average tumor volume reached ~330 mm 3 (P < 0.01 by two-way ANOVA, n = 5 mice; Fig. 5c,d) . In parallel, we monitored tumor growth by infusing G1-G10 at days 0 and 10 (~130 mm 3 ). Whereas CEA was unable to detect tumor burdens <330 mm 3 , ensemble urinary responses at day 10 were significantly elevated relative to those in samples before tumor growth, allowing the detection of tumors ~60 % smaller than those detectable with CEA (130 mm 3 compared to 330 mm 3 , respectively; Fig. 5e ). To further characterize the discriminatory sensitivity and specificity of these two approaches, we subjected serum CEA and urinary biomarker concentrations to ROC analysis. In contrast to the limited predictive power of CEA for early detection (AUC = 0.61), ensemble urinary fluorescence was highly discriminatory, producing a collective AUC of 0.94 (n = 10 mice; Fig. 5f ). To determine the underlying biomarkers driving the predictivity of the ensemble, the responses of the individual probes were quantified and plotted as ROC curves (Supplementary Figs. 17 and 18) . Disease classification by the best-performing individual probes (G1, G2 and G3, AUCs = 0.78-0.81) did not fully recapitulate the multiplexed set but was improved in the dual (G1 and G2, AUC = 0.88) and triple (G1, G2 and G3, AUC = 0.89) biomarker panels (Supplementary Fig. 19 ). This latter observation underscored the value of using a diverse family of probes for the most sensitive detection.
Having established the potential of biomarker amplification for early cancer detection, we sought crossvalidation in an independent cohort of CRC-bearing mice. In light of the high variability in CEA secretion rates, we hypothesized that our ensemble library of probes could detect tumors that secrete biomarkers at low rates. We selected HCT-15 cells, a genetically distinct CRC line that secretes CEA at a rate ~33% of the median value (Supplementary Fig. 14) . As anticipated by the >99% reduction in CEA production relative to LS174T tumors, growth of HCT-15 tumors could not be detected by serum analysis even at up to day 29, when the average tumor burden measured ~1,300 mm 3 (Fig. 5c,d) , the maximum allowable limit in this mouse model. By contrast, HCT-15 tumors were readily discriminated by nanoworm infusion and urine analysis at day 13 (~150 mm 3 ; Fig. 5c,e) , representing, at the minimum, a more than ninefold improvement in detection over CEA (150 mm 3 compared to 1,300 mm 3 , respectively). Collectively, these results showed that synthetic urinary biomarkers have the potential to detect cancer earlier compared to conventional blood biomarkers, with particularly marked enhancements for tumors secreting biomarkers at low rates.
DISCUSSION
An ideal biomarker should be secreted at high amounts relative to the native background, remain stable or persistent in circulation until detection, be readily accessible from compositionally simple host fluids and discriminate disease with high sensitivity and specificity. In practice, these parameters are often difficult to improve or control for naturally occurring biomarkers and, consequently, many promising biomarkers fail during rigorous evaluation for clinical translation. Here we devised a system of synthetic biomarkers with the capacity to (i) amplify biomarker concentrations through substrate turnover by targeting aberrant protease activities, (ii) release stable, d isomer-enriched mass reporters designed to be present within a narrow mass window free of host molecules, (iii) trigger reporter clearance from blood into urine to reduce matrix complexity and facilitate facile extraction and (iv) simultaneously monitor libraries of candidate synthetic biomarkers in vivo to identify and validate lead biomarkers. An enabling feature of our platform is the use of a nanoscale scaffold to direct the traffic of peptides in vivo. Although free peptides are typically cleared rapidly from the circulation through urinary secretion, we showed that nanoworm-conjugated peptides are endowed with long circulation times to allow transport into diseased tissues across porous vasculature and are present in urine only after release from nanoworms by disease-associated proteases. Several reports have highlighted the potential of applying peptide substrates to patient serum samples followed by mass spectrometry profiling to uncover disease-specific activity signatures 4, 29, 30, 41 . However, without a delivery mechanism, in vitro serum analysis cannot sample proteases expressed on the membrane of cells residing in the disease microenvironment (e.g., MMP9 expression by liver-resident macrophages in fibrosis). Similarly to blood biomarkers, secreted proteases are markedly diluted in the circulation and are often challenging to detect above highly abundant plasma proteins 5 , potent proteolytic cascades activated during sample collection (e.g., coagulation) and panprotease inhibitors in plasma (e.g., α 2 -macroglobulin). Here we chose nanoworms as chaperones because iron oxide nanoparticles are safe for use in humans, but a broad range of nontoxic scaffolds, including proteins and sugars (e.g., albumin and dextran, respectively), would also be amenable for peptide delivery. Given the cumulative wealth of nanomaterials, targeting ligands and enhanced delivery strategies available in nanomedicine, we expect this work to be transferrable to many additional formulations to gain access to different organs, types of vasculature and tissue depths 42, 43 .
Our library of isobaric mass tags to track the response of ten peptides in vivo provides a level of multiplexing that is currently challenging to attain with molecular and activity-based imaging probes [11] [12] [13] . The vast majority of these approaches make use of modified protease substrates that emit fluorescent signals after proteolytic cleavage. Consequently, substrate multiplexing is limited by emission overlap as well as the need to emit in the near-infrared window (600-900 nm) to minimize signal attenuation from tissue absorption, constraining most of these studies to single probes. Conversely, our work demonstrates the generation of a synthetic biomarker library that is five to ten times more densely multiplexed than existing state-of-the-art activity-based probes, compares favorably with commercial isobaric tags (e.g., 8-plex iTRAQ) and, with additional parent peptides, is extensible to hundreds of orthogonal mass codes.
In addition to its invasiveness, a major limitation of the core biopsy for liver fibrosis is that tissue specimens are only ~1/50,000th the size of an adult liver, leading to sampling variation that can result in inaccurate diagnosis or staging and repeat biopsies. Here we show how nanoparticles accumulate uniformly in the liver, penetrating without bias into regions of active fibrosis to release urinary biomarkers as integrated measures of disease burden. Our work in two models of fibrosis with different mechanisms of induction (i.e., xenobiotic compared to genetic) indicates the value of biomarker G7 for monitoring fibrosis. These results are reflective of fibrosis as a conserved tissue response to diverse chronic liver diseases (e.g., viral hepatitis, alcohol abuse or fatty liver disease) and suggest that biomarker G7 could be useful for monitoring fibrosis stemming from distinct underlying pathologies. Moving forward, an important area for future study will be elucidating the biological mechanisms that are ultimately responsible for the release of individual reporters. This could be accomplished, for example, by comparing urinary signatures from mice lacking specific proteases (e.g., Mmp9 −/− mice) to those of their wild-type counterparts or the use of clodronate liposomes to deplete liver macrophages to identify reporters that track with cellular inflammation.
A major factor preventing early detection of cancer is the tremendous dilution biomarkers experience on release from tumor cells into systemic circulation. Recent computational estimates 18 revealed that solid tumors could potentially remain undetectable for 10-12 years and reach spherical diameters >2.5 cm before biomarker concentrations become sufficiently elevated to indicate disease. The advantage of our system is the ability to amplify tumor responses by leveraging enzymatic turnover (i.e., a single copy of a protease can cleave hundreds of peptide substrates per hour) and the renal system's natural capacity to remove and concentrate plasma peptides into urine (i.e., from ~5 l of blood to 300 ml void volume). Our study shows that the combined effects of protease amplification and renal concentration can lead to promising results, such as the detection of small tumors that CEA could not discriminate even at the highest tumor burdens allowable in our mouse models. As many tumors do not secrete biomarkers at rates sufficient for detection (or at all), targeting tumor proteases should allow a broader range of cancers to be discovered at an early stage because proteases are uniformly implicated during tumor invasion and metastasis. Extension of this platform to multiple types of cancers would benefit from the development of cancer type-specific tests that could be accomplished by identifying unique biomarker panels for each cancer 44 . Conversely, a highly sensitive, pan-cancer test comprised of a single set of diverse probes would be useful in clinical settings when the primary tumor is already known, such as monitoring for recurrence or metastases after surgical resection of primary tumors.
The successful translation of this platform to humans would require further confirmation of our lead biomarkers in patients as well as quantification of the potential benefits of monitoring biomarker panels compared to single markers. A crucial limitation of existing single-biomarker assays is their relatively poor disease specificity (e.g., CEA is elevated in smokers). These assays can be improved by multiplexing (e.g., prenatal triple screening) or specifying their use in well-defined clinical contexts (e.g., prostate-specific antigen is now recommended for recurrence monitoring but not screening). Similarly, the ability of this platform to differentiate protease-driven diseases (e.g., inflammation compared to cancer) would benefit from multiplexing and serial measurements in high-risk populations.
A general concern with rodent studies is the relatively small number of animals used for hypotheses testing and validation. In this study, the number of mice selected per experimental condition (n = 5-10) allowed reasonable estimation of the mean and variance on the basis of a normal distribution. The statistical power of our study was further bolstered by the prominent effect sizes (e.g., large AUCs) in both diseases studied, as well as the concordant biomarker responses across distinct models. Nonetheless, looking forward and in light of recent expert recommendations regarding biomarker qualifications 37 , the results of this study will require further confirmation and rigorous evaluation in humans.
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A r t i c l e s
In summary, this study provides a framework for engineering diagnostic agents that can exploit fundamental features of human disease and physiology for noninvasive urinary monitoring. Future expansion and inclusion of additional enzymatic families (e.g., lipases, nucleases or glycosidases), organ-specific delivery strategies and broader multiplexing capabilities will provide opportunities for systems-level monitoring of disease and elucidating multienzymatic networks in health and disease.
METHODS
Methods and any associated references are available in the online version of the paper.
